Notes Payable |
Note
11 – Notes Payable
Notes
payable consists of the following at September 30, 2021 and December 31, 2020, respectively:
Schedule of Notes Payable
|
|
September
30, |
|
|
December
31, |
|
|
|
2021 |
|
|
2020 |
|
|
|
|
|
|
|
|
Total
notes payable |
|
|
919,274 |
|
|
|
334,841 |
|
On
September 24, 2021, the Company completed the sale of a (i) Promissory Note in the principal amount of $750,000
(the “Second AJB Note”) to AJB Capital Investments LLC (“AJB Capital”), (ii) a three-year
warrant to purchase 1,500,000
shares of the Company’s common stock at an initial exercise price of $0.25
per share, and (iii) a three-year
warrant to purchase 2,000,000
shares of the Company’s common stock at an initial exercise price of $0.50
per share, for an aggregate purchase price of $705,000,
pursuant to a Securities Purchase Agreement between the Company and AJB Capital (the “Purchase Agreement”). The Company
received net proceeds of $678,750
after deductions of debt discounts, consisting of $45,000
pursuant to an original issue discount, $15,000
of legal fees and $11,250
of brokerage fees.
The Note matures on September
24, 2022 (the “Maturity Date”), bears interest at a rate of 8%
per annum, and, following an event of default only, is convertible into shares of the Company’s common stock at a conversion
price equal to the lesser of 90% of the lowest trading price during (i) the 20
trading day period preceding the issuance date of the note, or (ii) the 20 trading day period preceding date of conversion of the
Note. The Note is also subject to covenants, events of defaults, penalties, default interest and other terms and conditions
customary in transactions of this nature. Pursuant to the Purchase Agreement, the Company paid a commitment fee to AJB Capital in
the amount of $250,000
(the “Commitment Fee”) in the form of 1,250,000
shares of the Company’s common stock (the “Commitment Fee Shares”). During the six month period following the six
month anniversary of the closing date, AJB Capital shall be entitled to be issued additional shares of common stock of the Company
to the extent AJB Capital’s sale of the Commitment Fee Shares has resulted in net proceeds in an amount less than the
Commitment Fee. The Commitment Fee Shares resulted in a debt discount of $150,062
that is being amortized over the life of the loan.
The obligations of the Company to AJB Capital under the Note and
the Purchase Agreement are secured by a lien on the Company’s assets pursuant to a Security Agreement between the Company and
AJB Capital.
|
|
$ |
750,000 |
|
|
$ |
- |
|
|
|
|
|
|
|
|
|
|
On
January 20, 2021, the Company completed the sale of a Promissory Note in the principal amount of $290,000
(the “First AJB Note”) to AJB Capital for a purchase price of $281,300,
pursuant to a Securities Purchase Agreement between the Company and AJB Capital (the “Purchase Agreement”). The Company
received net proceeds of $268,250
after deductions of debt discounts, consisting of $8,700
pursuant to an original issue discount, $7,250
of legal fees and $5,800
of brokerage fees.
The First AJB Note carried interest at a rate of 10%
per annum, was to mature on October
20, 2021, and was repaid in full on September 17, 2021.
Pursuant to the Purchase Agreement, the Company paid a
commitment fee to AJB Capital in the amount of $200,000
(the “Commitment Fee”) in the form of 2,000,000
shares of the Company’s common stock (the “Commitment Fee Shares”). As
the Company repaid the First AJB Note prior to the Maturity Date, the Company exercised its right to redeem 1,000,000 of the
Commitment Fee Shares for a nominal redemption price of $1.00. The issuance of the Commitment Fee Shares resulted in a debt
discount of $268,250
that was amortized over the life of the loan.
|
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
On
February 3, 2020, the Company, through its wholly-owned subsidiary, One World Pharma SAS, received an advance of 100,000,000 COP,
or $29,134 USD, from an individual pursuant to an unsecured promissory note due on demand that carried a 6% interest rate. The Company
repaid 50,000,000 COP, or $14,567 USD, during the year ended December 31, 2020, and repaid the remaining 50,000,000 COP, or $14,567
USD, during the period ending September 30, 2021. |
|
|
- |
|
|
|
14,567 |
|
|
|
|
|
|
|
|
|
|
On
December 16, 2020, the Company received an advance of $125,000 from our CEO, Isiah Thomas, III pursuant to an unsecured promissory
note due on demand that carried a 6% interest rate. A total of $130,610, consisting of $125,000 of principal and $5,610 of interest,
was repaid on September 15, 2021. |
|
|
- |
|
|
|
125,000 |
|
|
|
|
|
|
|
|
|
|
On
October 28, 2020, the Company received an advance of $50,000 from its CEO, Isiah Thomas, III pursuant to an unsecured promissory
note due on demand that carries a 6% interest rate. A total of $52,918, consisting of $50,000 of principal and $2,918 of interest,
was repaid on October 18, 2021. |
|
|
50,000 |
|
|
|
50,000 |
|
|
|
|
|
|
|
|
|
|
On
September 14, 2020, the Company received an advance of $26,000 from its Chairman, Dr. Kenneth Perego, II, M.D. pursuant to an unsecured
promissory note due on demand that carried a 6% interest rate. The advance was repaid by the Company on March 29, 2021. |
|
|
- |
|
|
|
26,000 |
|
|
|
|
|
|
|
|
|
|
On
May 4, 2020, the Company, through its wholly-owned subsidiary OWP Ventures, Inc., borrowed $119,274 from Customers Bank (“Lender”),
pursuant to a Promissory Note issued by OWP Ventures to Lender (the “PPP Note”). The loan was made pursuant to the Payroll
Protection Program established as part of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). The
PPP Note bears interest at 1.00% per annum, payable monthly beginning December 4, 2020, and is due on May 4, 2022. The PPP Note may
be repaid at any time without penalty.
Under the Payroll Protection Program, the Company will be eligible for loan
forgiveness up to the full amount of the PPP Note and any accrued interest. The forgiveness amount will be equal to the amount that
the Company spends during the 24-week period beginning May 4, 2020 on payroll costs, payment of rent on any leases in force prior
to February 15, 2020 and payment on any utility for which service began before February 15, 2020. The maximum amount of loan forgiveness
for non-payroll expenses is 40% of the amount of the PPP Note. No assurance is provided that the Company will obtain forgiveness
of the PPP Note in whole or in part.
The PPP Note contains customary events of default relating to, among other things,
payment defaults, breach of representations and warranties, or provisions of the promissory note. The occurrence of an event of default may result in a claim for the immediate repayment of all amounts outstanding under the PPP Note.
|
|
|
119,274 |
|
|
|
119,274 |
|
|
|
|
|
|
|
|
|
|
Total
notes payable |
|
|
919,274 |
|
|
|
334,841 |
|
Less
unamortized debt discounts |
|
|
558,696 |
|
|
|
- |
|
Notes
payable, net of discounts |
|
$ |
360,578 |
|
|
$ |
334,841 |
|
ONE
WORLD PHARMA, INC.
Notes
to Condensed Consolidated Financial Statements
(Unaudited)
The
Company recognized interest expense for the nine months ended September 30, 2021 and 2020, as follows:
Schedule of Interest Expenses
|
|
September
30, |
|
|
September
30, |
|
|
|
2021 |
|
|
2020 |
|
|
|
|
|
|
|
|
Interest
on convertible notes |
|
$ |
21,120 |
|
|
$ |
21,516 |
|
Interest
on notes payable |
|
|
8,434 |
|
|
|
7,055 |
|
Amortization
of debt discounts, including $286,345 of stock-based discounts |
|
|
310,633 |
|
|
|
- |
|
Interest
on accounts payable |
|
|
7,771 |
|
|
|
- |
|
Total
interest expense |
|
$ |
347,958 |
|
|
$ |
28,571 |
|
|